Tetrabenazine and movement disorders.
Based on blind review of videotape recordings, we analyzed the ability of tetrabenazine to suppress abnormal movements. The recordings were done before treatment, after 3 weeks on a stable dose (up to 200 mg daily) of tetrabenazine, and then after 3 weeks on placebo. Among the patients who completed the trial, improvement occurred in 6 of 8 with Huntington disease, 6 of 10 with tardive dyskinesia, and 3 of 8 with dystonic disorders. The drug was usually tolerated well.
D000328:Adult; D000368:Aged; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004409:Dyskinesia, Drug-Induced / Q000188:drug therapy; D004421:Dystonia / Q000188:drug therapy; D005260:Female; D006801:Humans; D006816:Huntington Disease / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D009069:Movement Disorders / Q000188:drug therapy*; D013747:Tetrabenazine / Q000009:adverse effects / Q000627:therapeutic use*
D013747:Tetrabenazine